Intravesical instillation of Bacillus Calmette-Guerin (BCG) hasbecome an established adjuvant treatment for superficial bladdercarcinoma. This treatment is associated with a relatively high rateof side effects which are mostly reversible spontaneously or canbe treated symptomatically. Serious systemic side effects are lessfrequent. One of rare complications is gran...

BACKGROUND To date, prophylactic intravesical chemotherapy after radical nephroureterectomy is one of the few available treatments that effectively prevent secondary bladder cancer. However, treating all patients with prophylactic intravesical chemotherapy is excessive for patients who are at a low risk or insensitive to the treatment. Thus, to guide individualized clinical treatment, in additi...

Summary Bladder cancer is a heterogeneous disease in molecular, histological and clinical aspects. Treatment should also be considered from different angles - surgery, intravesical chemo- or immunotherapy, radiation therapy lifestyle changes. Intravesical treatment of superficial bladder with Еpirubicin Bacillus Calmette-Guérin (BCG) continuation surgical to reduce eliminate further recurrence.

PURPOSE About 15% to 20% of patients with detrusor hyperreflexia do not benefit from oral oxybutynin regimens, frequently because of unpleasant side effects. Several reports indicate that intravesical oxybutynin is effective in many of these patients but there are some who still fail to respond. MATERIALS AND METHODS A select group of 10 adults with detrusor hyperreflexia unresponsive to stan...

OBJECTIVE The management of stage 1 and grade 3 (T1G3) bladder cancer continues to be controversial. Although the transurethral resection of bladder tumor (TURBT) followed by intravesical chemotherapy is a conservative strategy for treatment of T1G3 bladder cancer, a relatively high risk of tumor recurrence and progression remains regarding the therapy. This study aimed to compare the efficacy ...

The present study describes the histopathological and molecular effects of P-MAPA (Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride) intravesical immunotherapy combined with systemic doxorubicin or cisplatin for treatment of non-muscle invasive bladder cancer (NMIBC) in an appropriate animal model. Our results showed an undifferentiated tumor, characterizing a tumor ...

the aim of this investigation was to improve the storage stability and survival rate of intravesical bcg product, manufactured with an attenuated strain of mycobacterium bovis (pasteur strain 1173p2 of bcg) in the presence of sodium glutamate. formulations with various concentrations of trehalose (a known protectant) were developed as liquid and lyophilized forms. formulations were evaluated by...

In clinical settings, intravesical instillation of a drug bolus is often performed for the treatment of bladder diseases. However, it requires repeated instillations to extend drug efficacy, which may result in poor patient compliance. To alleviate this challenge, implantable devices have been developed for the purpose of sustained, intravesical drug delivery. In this review, we briefly summari...

Rare cases of tuberculous urinary tract or genital infection caused by intravesical Intravesical Bacillus Calmette-Guerin (BCG) instillation therapy have been reported. We encountered a patient with tuberculous granuloma in the scrotal skin after intravesical BCG therapy for bladder cancer. There was evidence of infection in the scrotal skin, but not in the epididymis. To the best of our knowle...